Category Archives: Patent Eligible Subject Matter

Is the Patent Eligibility Act a Panacea for Claims to Diagnostics?

On January 23, the Subcommittee on Intellectual Property held a hearing in which the members of the committee heard testimony about the Patent Eligibility Restoration Act (PERA) introduced by Senators Coons and Tillis. I have considered case law directed to … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Does the “Patent Eligibility Restoration Act of 2023” Revive Diagnostic Claims?

On June 22, Senator Chris Coons, along with Thom Tillis introduced the “Patent Eligibility Restoration Act of 2023” (hereinafter “the Act”) to amend 35 USC s. 101 to clarify the scope of patent-eligible subject matter. Section 100 would be amended … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Chromadex v. Elysium Health – It’s Only Natural!

On February 13, 2023, a Fed. Cir. panel of Judges Prost, Chen and Stoll (Prost writing) held, in Appeal no. 2022-1116, that the asserted claims 1-3 of U.S. Patent No. 8,197, 807 are directed to unpatentable subject matter, namely to … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

PTO Expands the Scope of the Immunotherapy Pilot Program

The PTO’s Cancer Immunotherapy Pilot Project, begun in 2016, has been deemed a success. It permitted an applicant claiming a method to treat cancer using immunotherapy to file a petition to accelerate issuance of the first Examination Report. When the … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment